Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update.
Tai TW, Huang CF, Huang HK, Yang RS, Chen JF, Cheng TT, Chen FP, Chen CH, Chang YF, Hung WC, Han DS, Chan DC, Tsai CC, Chen IW, Chan WP, Chang HJ, Hwang JS, Wu CH. Tai TW, et al. Among authors: chen iw, chen ch, chen jf, chen fp. J Formos Med Assoc. 2023;122 Suppl 1:S4-S13. doi: 10.1016/j.jfma.2023.01.007. Epub 2023 Feb 11. J Formos Med Assoc. 2023. PMID: 36781371 Free article. Review.
Asia-pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures.
Huang CF, Chen JF, Reid IR, Chan WP, Ebeling PR, Langdahl B, Tu ST, Matsumoto T, Chan DC, Chung YS, Chen FP, Lewiecki EM, Tsai KS, Yang RS, Ang SB, Huang KE, Chang YF, Chen CH, Lee JK, Ma HI, Xia W, Mithal A, Kendler DL, Cooper C, Hwang JS, Wu CH. Huang CF, et al. Among authors: chen ch, chen jf, chen fp. J Formos Med Assoc. 2023;122 Suppl 1:S14-S20. doi: 10.1016/j.jfma.2023.01.013. Epub 2023 Feb 10. J Formos Med Assoc. 2023. PMID: 36775679 Free article.
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. McClung MR, et al. Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31. Lancet Diabetes Endocrinol. 2019. PMID: 31676222 Clinical Trial.
Caffeine: a potential mechanism for anti-obesity.
Wang M, Guo W, Chen JF. Wang M, et al. Among authors: chen jf. Purinergic Signal. 2024 May 28. doi: 10.1007/s11302-024-10022-1. Online ahead of print. Purinergic Signal. 2024. PMID: 38802651 Review.
1,426 results